Home > Boards > US OTC > Medical - Drugs > Provectus Biopharmaceuticals Inc. (PVCT)
Followed By 83
Posts 11283
Boards Moderated 0
Alias Born 11/02/2003

Thursday, January 27, 2022 10:34:49 AM

Re: None

Post# of 9821
NEWS -- Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better

KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in vaccines for cancer and viruses to improve immune response upon vaccination, in conjunction with the Company’s ongoing efforts to expand its intellectual property.

On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus’ patent application entitled “Halogenated Xanthenes as Vaccine Adjuvants” (publication no. US 2022/0016242 A1), which contained among other things:
  • In vitro data that showed PV-10 was able to significantly increase numbers of interferon (IFN) gamma-producing CD8 cells (compared to controls) for peptides representing various antigenic regions of the Hepatitis B virus (HBV) core protein (HBcAg). These peptides were selected for their capability to raise CD4 and CD8 T cells against HBV.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Immune adjuvants can help vaccines generate quicker, more efficacious and durable immune responses. This new research further supports the multi-faceted immunogenicity of Provectus’ small molecule medical science platform, which is the foundation of our work to develop transformative, accessibly-priced immunotherapy medicines.”

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at https://www.provectusbio.com.

Trademark

PV-10® is registered trademark of Provectus Pharmatech, Knoxville, Tennessee, U.S.A.

FORWARD-LOOKING STATEMENTS

The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.


###

Contact:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
Recent PVCT News

Pacific Booker Minerals Inc. Announces Annuals Posted and Project Update PBMLF Jul 1, 2022 9:30 AM

Maison Luxe Reports Best Ever Annual Revenues of Approximately $ 17.6 mil. for 2022 as Compared to Approximately $ 5.2 mil. for 2021, an Increase of Over 300% and Poised for Rapid Expansion in 2023 MASN Jun 30, 2022 9:58 AM

Global Fiber Technologies Secures Second Round of Inventory Financing GFTX Jun 30, 2022 9:41 AM

Sugarmade Announces Fully Executed LOI Toward Minority Stake Acquisition of Turnkey Cannabis Cultivation Property SGMD Jun 30, 2022 8:30 AM

HPIL(HPIL) Updates Shareholders HPIL Jun 30, 2022 8:30 AM

Emerging Markets Report: Cheaper. Simpler. More efficient. Ready to scale. SPYR Jun 29, 2022 11:41 AM

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System ONPH Jun 29, 2022 9:23 AM

Infobird Co., Ltd Provides Digital and Intelligent Customer Engagement Solution to Enhance Patient Vaccination Notification Services for a Top-10 Global Pharmaceutical Company's Subsidiary IFBD Jun 29, 2022 8:34 AM

Goldshore Resources Drills 78.35m at 1.17 g/t Au  and delineates higher grade lenses within Moss lake Deposit GSHRF Jun 29, 2022 8:33 AM

PSYC Provides Encouraging Update on its Investment in The Conscious Fund PSYC Jun 29, 2022 8:30 AM

Health Advance Inc. (OTC: HADV): Embrace their CBD Innovation Before Everyone Else Does! HADV Jun 29, 2022 8:00 AM

Resgreen Group Announces LilBuddy ™ Pilot Testing of Payload Capacity Exceeding Original Expectations RGGI Jun 29, 2022 6:00 AM

IGEN's CEO provides mid-year progress update for 2022 IGEN Jun 29, 2022 6:00 AM

Splash Beverage Group to Distribute TapouT through Save-A-Lot Grocery Stores in 32 States. SBEV Jun 28, 2022 8:23 AM

RYU Apparel Inc. (TSXV: RYU) (OTCQB: RYPPF) Announces Company Achievements and Roadmap For Shareholders with growth in Operations, Rollup Acquisition Strategy, and Disruptive Technology Opportunities RYPPF Jun 27, 2022 11:48 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y